B-cell activity in children with malaria

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Korir, Jackson C ^a,b,c   Magambo, Japhet K ^b   Mwatha, Joseph K ^a   Waitumbi, John N ^a  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Kenya)

^c MASINDE MULIRO UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT C3D,G; COMPLEMENT COMPONENT C3B; PEPTIDE FRAGMENT;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CASE CONTROL STUDY; CELL ACTIVITY; CHILDHOOD DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; KENYA; LYMPHOCYTE COUNT; MACROPHAGE; MALARIA; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; BLOOD; CELL PROLIFERATION; HOSPITALIZATION; IMMUNOLOGY; INFANT; LYMPHOCYTE ACTIVATION; MALARIA FALCIPARUM; PARASITOLOGY; PATHOLOGY; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; SOLUBILITY;

ANEMIA; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL PROLIFERATION; CHILD, PRESCHOOL; COMPLEMENT C3B; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; INFANT; KENYA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALARIA, FALCIPARUM; PEPTIDE FRAGMENTS; PLASMODIUM FALCIPARUM; RECEPTORS, COMPLEMENT 3D; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

EID: 84857932066     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-66     Document Type: Article

References (38)

1. WHO, World malaria report 2008 Geneva: World Health Organization 2008
2. Clinical features and pathogenesis of severe malaria. Mackintosh CL, Beeson JG, Marsh K, Trends Parasitol 2004 20 597 603 10.1016/j.pt.2004.09.006 15522670 (Pubitemid 39446751)
3. Malaria pathogenesis. Miller LH, Good MF, Milon G, Science 1994 264 1878 1883 10.1126/science.8009217 8009217 (Pubitemid 24245626)
4. Loss of red blood cell-complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia. Stoute JA, Odindo AO, Owuor BO, Mibei EK, Opollo MO, Waitumbi JN, J Infect Dis 2003 187 522 525 10.1086/367712 12552440 (Pubitemid 36184597)
5. Red cell surface changes and erythrophagocytosis in children with severe Plasmodium falciparum anemia. Waitumbi JN, Opollo MO, Muga RO, Misore AO, Stoute JA, Blood 2000 95 1481 1486 10666228 (Pubitemid 30099864)
6. The regulation of complement on cell surfaces. Devine DV, Transfus Med Rev 1991 5 123 131 10.1016/S0887-7963(91)70199-5 1726550
7. Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones. Arvieux J, Yssel H, Colomb MG, Immunology 1988 65 229 235 2973431
8. Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells. Thornton BP, Vetvicka V, Ross GD, Clin Exp Immunol 1996 104 531 537 10.1046/j.1365-2249.1996. 57761.x 9099940
9. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. Pangburn MK, Pangburn KL, Koistinen V, Meri S, Sharma AK, J Immunol 2000 164 4742 4751 10779780 (Pubitemid 30238075)
10. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. Thornton BP, Vetvicka V, Ross GD, J Immunol 1994 152 1727 1737 8120381 (Pubitemid 24075703)
11. Floating the raft hypothesis: lipid rafts play a role in immune cell activation. Cherukuri A, Dykstra M, Pierce SK, Immunity 2001 14 657 660 10.1016/S1074-7613(01)00156-X 11420035 (Pubitemid 32592412)
12. The CD19/CD21 signal transduction complex of B lymphocytes. Tedder TF, Zhou LJ, Engel P, Immunol Today 1994 15 437 442 10.1016/0167-5699(94)90274-7 7524521 (Pubitemid 24272189)
13. Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. Boyd AW, Anderson KC, Freedman AS, Fisher DC, Slaughenhoupt B, Schlossman SF, Nadler LM, J Immunol 1985 134 1516 1523 3871451 (Pubitemid 15135916)
14. Human marginal zone B cells are not an activated B cell subset: strong expression of CD21 as a putative mediator for rapid B cell activation. Timens W, Boes A, Poppema S, Eur J Immunol 1989 19 2163 2166 10.1002/eji.1830191129 2532141 (Pubitemid 20017727)
15. Decreased C3b receptors (CR1) on erythrocytes from patients with systemic lupus erythematosus. Holme E, Fyfe A, Zoma A, Veitch J, Hunter J, Whaley K, Clin Exp Immunol 1986 63 41 48 2937582 (Pubitemid 16196399)
16. A critical role for complement in maintenance of self-tolerance. Prodeus AP, Goerg S, Shen LM, Pozdnyakova OO, Chu L, Alicot EM, Goodnow CC, Carroll MC, Immunity 1998 9 721 731 10.1016/S1074-7613(00)80669-X 9846493 (Pubitemid 28557600)
17. Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases. Walport MJ, Lachmann PJ, Arthritis Rheum 1988 31 153 158 10.1002/art.1780310201 3279961
18. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Wilson JG, Ratnoff WD, Schur PH, Fearon DT, Arthritis Rheum 1986 29 739 747 10.1002/art.1780290606 2941021 (Pubitemid 16094151)
19. Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site. Myones BL, Ross GD, Complement 1987 4 87 98 3497773
20. Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia. Ling N, Hansel T, Richardson P, Brown B, Clin Exp Immunol 1991 84 16 22 1849806
21. Determination of soluble CD21 as a parameter of B cell activation. Huemer HP, Larcher C, Prodinger WM, Petzer AL, Mitterer M, Falser N, Clin Exp Immunol 1993 93 195 199 8348744 (Pubitemid 23238026)
22. Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia. Tooze JA, Bevan DH, Clin Exp Immunol 1991 83 423 429 1825940
23. Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia. Lowe J, Brown B, Hardie D, Richardson P, Ling N, Immunol Lett 1989 20 103 109 10.1016/0165-2478(89)90093-X 2523865 (Pubitemid 19043305)
24. Alterations in Serum Proteins and 19s Antibody Production during the Course of Induced Malarial Infections in Man. Abele DC, Tobie JE, Hill GJ, Contacos PG, Evans CB, Am J Trop Med Hyg 1965 14 191 197 14270444
25. Increased B cell survival and preferential activation of the memory compartment by a malaria polyclonal B cell activator. Donati D, Mok B, Chene A, Xu H, Thangarajh M, Glas R, Chen Q, Wahlgren M, Bejarano MT, J Immunol 2006 177 3035 3044 16920940 (Pubitemid 44277820)
26. Complement consumption in children with Plasmodium falciparum malaria. Nyakoe NK, Taylor RP, Makumi JN, Waitumbi JN, Malar J 2009 8 7 10.1186/1475-2875-8-7 19134190
27. Loss of red blood cell-complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia. Stoute JA, Odindo AO, Owuor BO, Mibei EK, Opollo MO, Waitumbi JN, J Infect Dis 2003 187 522 525 10.1086/367712 12552440 (Pubitemid 36184597)
28. Anti-ssDNA and antinuclear antibodies in human malaria. Adu D, Williams DG, Quakyi IA, Voller A, Anim-Addo Y, Bruce-Tagoe AA, Johnson GD, Holborow EJ, Clin Exp Immunol 1982 49 310 316 6982135 (Pubitemid 12097358)
29. Serum immunoglobulin levels in human malaria and their relationship to antibody production. Tobie JE, Abele DC, Wolff SM, Contacos PG, Evans CB, J Immunol 1966 97 498 505 4163253
30. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21). Prodinger WM, Schwendinger MG, Schoch J, Kochle M, Larcher C, Dierich MP, J Immunol 1998 161 4604 4610 9794388 (Pubitemid 28492033)
31. Processing of C3b-opsonized immune complexes bound to non-complement receptor 1 (CR1) sites on red cells: phagocytosis, transfer, and associations with CR1. Craig ML, Waitumbi JN, Taylor RP, J Immunol 2005 174 3059 3066 15728520 (Pubitemid 40279727)
32. In vivo decrease in the expression of complement receptor 2 on B-cells in HIV infection. Scott ME, Landay AL, Lint TF, Spear GT, AIDS 1993 7 37 41 10.1097/00002030-199301000-00006 8442917 (Pubitemid 23069030)
33. Floating the raft hypothesis: the roles of lipid rafts in B cell antigen receptor function. Cheng PC, Cherukuri A, Dykstra M, Malapati S, Sproul T, Chen MR, Pierce SK, Semin Immunol 2001 13 107 114 10.1006/smim.2000.0302 11308294 (Pubitemid 32382332)
34. Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia. Ling N, Hansel T, Richardson P, Brown B, Clin Exp Immunol 1991 84 16 22 1849806
35. Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren's syndrome but not juvenile arthritis. Masilamani M, Nowack R, Witte T, Schlesier M, Warnatz K, Glocker MO, Peter HH, Illges H, Scand J Immunol 2004 60 625 630 10.1111/j.0300-9475.2004.01494.x 15584974 (Pubitemid 39665108)
36. Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis. Masilamani M, von Kempis J, Illges H, Rheumatology (Oxford) 2004 43 186 190 (Pubitemid 38219673)
37. Functional properties of soluble CD21. Fremeaux-Bacchi V, Kolb JP, Rakotobe S, Kazatchkine MD, Fischer EM, Immunopharmacology 1999 42 31 37 10.1016/S0162-3109(99)00026-0 10408363 (Pubitemid 29322285)
38. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23. Fremeaux-Bacchi V, Bernard I, Maillet F, Mani JC, Fontaine M, Bonnefoy JY, Kazatchkine MD, Fischer E, Eur J Immunol 1996 26 1497 1503 10.1002/eji.1830260714 8766552 (Pubitemid 26229994)